Azenta/$AZTA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Azenta
Azenta Inc provides biological and chemical sample exploration and management solutions, using precision automation and cryogenics to develop automated ultra-cold storage. It serves customers from research to commercialization with sample management, automated storage, genomic services, consumables, informatics, and repository services. The company operates through two segments: Sample Management Solutions, offering SRS and Core Products such as automated stores, cryogenic systems, sample tubes, consumables, instruments, and thawing devices, which generate majority of its revenue; and Multiomics, which provides genomic analysis services. The company operates in United States, China, United Kingdom, rest of Europe, and others, with majority of its revenue in the United States.
- Ticker
- $AZTA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,900
- Headquarters
- Burlington, United States
- Website
- www.azenta.com
Azenta Metrics
BasicAdvanced
$1.7B
-
-$2.70
1.38
-
Price and volume
Market cap
$1.7B
Beta
1.38
52-week high
$46.41
52-week low
$15.93
Average daily volume
1.1M
Financial strength
Current ratio
2.5
Quick ratio
1.744
Long term debt to equity
0.036
Total debt to equity
0.036
Profitability
EBITDA (TTM)
29.211
Gross margin (TTM)
44.06%
Net profit margin (TTM)
-20.02%
Operating margin (TTM)
-3.70%
Effective tax rate (TTM)
26.38%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-0.73%
Return on equity (TTM)
-7.04%
Valuation
Price to revenue (TTM)
2.913
Price to book
1.13
Price to tangible book (TTM)
1.95
Price to free cash flow (TTM)
180.964
Free cash flow yield (TTM)
0.55%
Free cash flow per share (TTM)
0.216
Growth
Revenue change (TTM)
4.80%
Earnings per share change (TTM)
6.15%
3-year revenue growth (CAGR)
-0.88%
10-year revenue growth (CAGR)
1.13%
3-year earnings per share growth (CAGR)
70.09%
10-year earnings per share growth (CAGR)
9.62%
What the Analysts think about Azenta
Analyst ratings (Buy, Hold, Sell) for Azenta stock.
Analyst projections of the future price of Azenta stock.
Bulls say / Bears say
Azenta’s third-quarter revenue rose 12%, with 9% organic growth, and the company raised its full-year organic outlook to flat-to-up 1%. The stronger quarter suggests the recovery may be gaining traction. (Azenta)
Sample Management Solutions revenue grew 14% in the quarter, led by repository services and consumables and instruments. Strength in these recurring businesses may make revenue more resilient than sales of large equipment alone. (Azenta)
The improved outlook still points to little underlying growth: Azenta expects full-year organic revenue to be flat to up 1%, with Multiomics around flat to slightly down. Management also flagged cautious customer spending and uncertain timing for large equipment orders. (Azenta)
CEO John Marotta resigned in August, and a permanent replacement is still being sought. Leadership uncertainty adds execution risk while Azenta is trying to complete a turnaround. (Azenta)
Azenta plans to close three North American Multiomics labs and reduce staff, with $11–13 million of expected charges and about $7 million in cash costs. The projected $11 million of annual savings will take time to realise, leaving near-term costs and execution risk. (StockTitan)
Data summarised monthly by Lightyear AI. Last updated on 17 Oct 2026.
Azenta Financial Performance
Revenues and expenses
Azenta Earnings Performance
Company profitability
Upcoming events
No upcoming events
Azenta News
AllArticlesVideos
ROSEN, A LEADING LAW FIRM, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA
Newsfile Corp12 hours ago
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA
Newsfile Corp4 days ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages Azenta, Inc. Investors to Inquire About Securities Class Action Investigation - AZTA
Newsfile Corp5 days ago
Funds containing Azenta
AllUSDEURGBP
Fund name | Fund size | $AZTA weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.09% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.09% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.06% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.06% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.